

CONTENTS

<i>Contributors</i>	<i>ix</i>
<i>Preface</i>	<i>xiii</i>
<i>Volumes in series</i>	<i>xv</i>

Section IV. Peptides **1**

1. Stapled Peptides for Intracellular Drug Targets **3**

Gregory L. Verdine and Gerard J. Hilinski

1. Introduction	4
2. All-Hydrocarbon Stapled α -Helical Peptides	6
3. The Design of Stapled Peptides	9
4. Stapled Peptide Synthesis	12
5. Olefin Metathesis	16
6. N-terminal and Internal Modifications	16
7. Cleavage of Stapled Peptides from the Solid Support	19
8. Stapled Peptide Purification	20
9. Biophysical Characterization	20
10. Cell Permeability	23
11. <i>In Vitro</i> Target Interaction and Activity Assays	26
12. <i>In Vivo</i> Efficacy	27
13. Strategies for Stapled Peptide Optimization	28
14. Summary	30
Acknowledgments	30
References	30

2. Mapping of Vascular ZIP Codes by Phage Display **35**

Tambet Teesalu, Kazuki N. Sugahara, and Erkki Ruoslahti

1. Introduction	36
2. Methods	41
3. Concluding Remarks and Perspectives	52
Acknowledgments	53
References	53

3. Engineering Cyclic Peptide Toxins	57
Richard J. Clark and David J. Craik	
1. Introduction	58
2. Peptide Design	59
3. Peptide Synthesis	60
4. Structural Analysis	66
5. Stability Assays	68
6. Special Considerations for Cyclic Peptides	69
Acknowledgments	71
References	71
4. Peptide Discovery Using Bacterial Display and Flow Cytometry	75
Jennifer A. Getz, Tobias D. Schoep, and Patrick S. Daugherty	
1. Introduction	76
2. Protocols	79
3. Conclusions	94
Acknowledgments	95
References	95
Section V. Scaffolds	99
5. Designed Ankyrin Repeat Proteins (DARPs): From Research to Therapy	101
Rastislav Tamaskovic, Manuel Simon, Nikolas Stefan, Martin Schwill, and Andreas Plückthun	
1. Introduction	102
2. Applications of DARPs	107
3. Protocols for DARPs in Biomedical Applications	112
Acknowledgment	129
References	129
6. Target-Binding Proteins Based on the 10th Human Fibronectin Type III Domain (¹⁰F_n3)	135
Shohei Koide, Akiko Koide, and Daša Lipovšek	
1. Introduction	136
2. Library Design	137
3. Choice of Selection Platform	139
4. Phage Display, mRNA Display, and Yeast-Surface Display of ¹⁰ F _n 3-Based Libraries	141
5. Production	151

6. Conclusion	153
Acknowledgments	154
References	154
7. Anticalins: Small Engineered Binding Proteins Based on the Lipocalin Scaffold	157
Michaela Gebauer and Arne Skerra	
1. Introduction	158
2. Cloning and Expression of Lipocalins and Anticalins in <i>E. coli</i>	166
3. Construction of a Genetic Anticalin Library	170
4. Preparation and Selection of a Phage Display Library for Anticalins	172
5. Preparation and Selection of a Bacterial Surface Display Library for Anticalins	176
6. Colony Screening for Anticalins with Specific Target-Binding Activity	177
7. Screening for Anticalins with Specific Target-Binding Activity Using Microtiter Plate Expression in <i>E. coli</i>	179
8. Measuring Target Affinity of Anticalins in an ELISA	181
9. Measuring Target Affinity of Anticalins via Surface Plasmon Resonance	182
10. Application of Anticalins in Biochemical Research and Drug Development	184
References	186
8. T Cell Receptor Engineering	189
Jennifer D. Stone, Adam S. Chervin, David H. Aggen, and David M. Kranz	
1. Introduction	190
2. Stability and Affinity Engineering of T Cell Receptors by Yeast Surface Display	192
3. Affinity Engineering and Selection of T Cell Receptors by T Cell Display	200
4. Expression, Purification, and Applications of Soluble scTv Proteins	207
5. Recipes for Media and Buffers	215
Acknowledgments	218
References	219
9. Engineering Knottins as Novel Binding Agents	223
Sarah J. Moore and Jennifer R. Cochran	
1. Introduction	224
2. Knottins as Scaffolds for Engineering Molecular Recognition	225
3. Engineering Knottins by Yeast Surface Display	227
4. Knottin Library Construction	230
5. Screening Yeast-Displayed Knottin Libraries	234
6. Knottin production by chemical synthesis or recombinant expression	237
7. Cell binding assays	243

8. Summary	247
Acknowledgments	247
References	247

Section VI. Pharmacokinetics **253**

10. Practical Theoretic Guidance for the Design of Tumor-Targeting Agents **255**

K. Dane Wittrup, Greg M. Thurber, Michael M. Schmidt, and John J. Rhoden

1. Introduction	256
2. What Molecular Size Is Best for Tumor Uptake?	256
3. Will Targeting Increase Nanoparticle Accumulation in a Tumor?	259
4. How Does Affinity Affect Biodistribution?	261
5. What Dose Is Necessary in Order to Overcome the "Binding Site Barrier"?	263
6. Conclusions	264
References	265

11. Reengineering Biopharmaceuticals for Targeted Delivery Across the Blood-Brain Barrier **269**

William M. Pardridge and Ruben J. Boado

1. Introduction	270
2. Blood-Brain Barrier Receptor-Mediated Transport and Molecular Trojan Horses	271
3. Reengineering Recombinant Proteins for Targeted Brain Delivery	274
4. Genetic Engineering of Expression Plasmid DNA Encoding IgG Fusion Proteins	278
5. Pharmacokinetics and Brain Uptake of IgG Fusion Proteins	279
6. CNS Pharmacological Effects of IgG Fusion Proteins	284
7. Immune Response Against IgG Fusion Proteins	287
8. Summary	288
References	289

12. Engineering and Identifying Supercharged Proteins for Macromolecule Delivery into Mammalian Cells **293**

David B. Thompson, James J. Cronican, and David R. Liu

1. Introduction	294
2. Methods	301
3. Conclusion	317
References	318

<i>Author Index</i>	321
<i>Subject Index</i>	341